Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Human Papillomavirus | Research article

Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention

Authors: Pedro Surriabre, Andrea Torrico, Tania Vargas, Fuantina Ugarte, Patricia Rodriguez, Véronique Fontaine

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

HPV test implementation as a primary screening tool has the potential to decrease cervical cancer incidence as shown by several studies around the world. However, in many low-resource settings, the HPV test introduction has been backed down mainly due to its price. In this study, we present a novel low-cost strategy involving simple devices and techniques for high-risk human papillomavirus (HR-HPV) detection. The analytical performance to detect HR-HPV infections of this novel strategy was assessed by comparing it with the Hybrid Capture 2 system (HC2), which is used as gold standard.

Methods

Paired-cervical samples were collected from 541 women assisting to gynecological services in an outpatient clinic. One sample was transported in the Hybrid Capture Standard Transport Medium for HR-HPV detection by the HC2. The second sample was transported on glass slide for detection by PCR-based techniques (GP-EIA, BSGP-EIA and pU 1 M-L/2R).

Results

The level of agreement between the PCR-based techniques and HC2 system was determined with the Cohen’s kappa value. The kappa values between HC2 and GP-EIA, BSGP-EIA and pU 1 M-L/2R were 0.71 (CI 95% 0.63–0.78), 0.78 (CI 95% 0.71–0.84) and 0.63 (CI 95% 0.55–0.72), respectively. However, when the results from both BSGP-EIA and pU 1 M-L/2R were combined, the level of agreement with HC2 was increased to 0.82 (CI 95% 0.76–0.88), reflecting a very good agreement between the two HR-HPV detection strategies. Furthermore, the sensitivity of both techniques combined was also increased compared to the BSGP-EIA (88.7% vs 77.4%) and the pU (88.7 vs 60.9%) without penalizing the specificity obtained with the BSGP-EIA (95.1% vs 96.9%) and the pU (95.1% vs 96.5%).

Conclusions

This novel strategy, combining two PCR-based techniques for HR-HPV detection, could be useful for cervical cancer screening in self-collected samples in low-income countries.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
2.
go back to reference Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–88.CrossRefPubMed Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–88.CrossRefPubMed
3.
go back to reference Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:CD008587.PubMed Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:CD008587.PubMed
4.
go back to reference Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99.CrossRefPubMed Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99.CrossRefPubMed
5.
go back to reference Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefPubMed Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefPubMed
6.
go back to reference Dzuba IG, Calderón R, Bliesner S, Luciani S, Amado F, Jacob M. A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. Pan Am J Public Health. 2005;18:53–63.CrossRef Dzuba IG, Calderón R, Bliesner S, Luciani S, Amado F, Jacob M. A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. Pan Am J Public Health. 2005;18:53–63.CrossRef
7.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRef
8.
go back to reference Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10.
9.
go back to reference Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed
10.
go back to reference Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S3/78–89. Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S3/78–89.
11.
go back to reference Arbyn M, Snijders PJF, Meijer CJLM, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817–26.CrossRefPubMed Arbyn M, Snijders PJF, Meijer CJLM, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817–26.CrossRefPubMed
12.
go back to reference Surriabre P, Allende G, Prado M, Cáceres L, Bellot D, Torrico A, et al. Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA. BMC Womens Health. 2017;17:135.CrossRefPubMedPubMedCentral Surriabre P, Allende G, Prado M, Cáceres L, Bellot D, Torrico A, et al. Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA. BMC Womens Health. 2017;17:135.CrossRefPubMedPubMedCentral
13.
go back to reference Rymsza T, Ribeiro EA, de Carvalho LFDCES, Bhattacharjee T, de Azevedo Canevari R. Human papillomavirus detection using PCR and ATR-FTIR for cervical cancer screening. Spectrochim Acta A Mol Biomol Spectrosc. 2018;196:238–46.CrossRefPubMed Rymsza T, Ribeiro EA, de Carvalho LFDCES, Bhattacharjee T, de Azevedo Canevari R. Human papillomavirus detection using PCR and ATR-FTIR for cervical cancer screening. Spectrochim Acta A Mol Biomol Spectrosc. 2018;196:238–46.CrossRefPubMed
14.
go back to reference Yang H, Li L-J, Xie L-X, Luo Z-Y, Lu M, Lin M, et al. Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China. Arch Virol. 2016;161:449–54.CrossRefPubMed Yang H, Li L-J, Xie L-X, Luo Z-Y, Lu M, Lin M, et al. Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China. Arch Virol. 2016;161:449–54.CrossRefPubMed
15.
go back to reference Ambulos NP, Schumaker LM, Mathias TJ, White R, Troyer J, Wells D, et al. Next-generation sequencing-based HPV genotyping assay validated in formalin-fixed, paraffin-embedded Oropharyngeal and cervical Cancer specimens. J Biomol Tech. 2016;27:46–52.CrossRefPubMedPubMedCentral Ambulos NP, Schumaker LM, Mathias TJ, White R, Troyer J, Wells D, et al. Next-generation sequencing-based HPV genotyping assay validated in formalin-fixed, paraffin-embedded Oropharyngeal and cervical Cancer specimens. J Biomol Tech. 2016;27:46–52.CrossRefPubMedPubMedCentral
16.
go back to reference Micalessi MI, Boulet GA, Bogers J. A real-time PCR approach based on SPF10 primers and the INNO-LiPA HPV genotyping extra assay for the detection and typing of human papillomavirus. Methods Mol Biol. 2015;1249:27–35.CrossRefPubMed Micalessi MI, Boulet GA, Bogers J. A real-time PCR approach based on SPF10 primers and the INNO-LiPA HPV genotyping extra assay for the detection and typing of human papillomavirus. Methods Mol Biol. 2015;1249:27–35.CrossRefPubMed
17.
go back to reference da Fonseca AJ, Galvão RS, Miranda AE, Ferreira LC, Chen Z. Comparison of three human papillomavirus DNA detection methods: next generation sequencing, multiplex-PCR and nested-PCR followed by sanger based sequencing. J Med Virol. 2016;88:888–94.CrossRefPubMed da Fonseca AJ, Galvão RS, Miranda AE, Ferreira LC, Chen Z. Comparison of three human papillomavirus DNA detection methods: next generation sequencing, multiplex-PCR and nested-PCR followed by sanger based sequencing. J Med Virol. 2016;88:888–94.CrossRefPubMed
18.
go back to reference Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol. 2010;48:143–9.CrossRefPubMed Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol. 2010;48:143–9.CrossRefPubMed
19.
go back to reference Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–20.CrossRefPubMedPubMedCentral Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–20.CrossRefPubMedPubMedCentral
20.
go back to reference Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006;44:3680–5.CrossRefPubMedPubMedCentral Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006;44:3680–5.CrossRefPubMedPubMedCentral
21.
go back to reference Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110:94–101.CrossRefPubMed Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110:94–101.CrossRefPubMed
22.
go back to reference Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol. 2009;47:541–6.CrossRefPubMedPubMedCentral Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol. 2009;47:541–6.CrossRefPubMedPubMedCentral
23.
go back to reference Chan PKS, Cheung T-H, Tam AOY, Lo KWK, Yim S-F, Yu MMY, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer. 2006;118:243–5.CrossRefPubMed Chan PKS, Cheung T-H, Tam AOY, Lo KWK, Yim S-F, Yu MMY, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer. 2006;118:243–5.CrossRefPubMed
24.
go back to reference Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997;35:1304–10.PubMedPubMedCentral Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997;35:1304–10.PubMedPubMedCentral
25.
go back to reference Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46:1050–9.CrossRefPubMedPubMedCentral Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46:1050–9.CrossRefPubMedPubMedCentral
26.
go back to reference Evans MF, Adamson CSC, Simmons-Arnold L, Cooper K. Touchdown general primer (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of human papillomavirus. BMC Clin Pathol. 2005;5:10.CrossRefPubMedPubMedCentral Evans MF, Adamson CSC, Simmons-Arnold L, Cooper K. Touchdown general primer (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of human papillomavirus. BMC Clin Pathol. 2005;5:10.CrossRefPubMedPubMedCentral
27.
go back to reference de San JS, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.CrossRef de San JS, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.CrossRef
28.
go back to reference Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia SR, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–56.CrossRefPubMed Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia SR, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–56.CrossRefPubMed
29.
go back to reference Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 1991;72(Pt 5):1039–44.CrossRefPubMed Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 1991;72(Pt 5):1039–44.CrossRefPubMed
30.
go back to reference Kado S, Kawamata Y, Shino Y, Kasai T, Kubota K, Iwasaki H, et al. Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol. 2001;81:47–52.CrossRefPubMed Kado S, Kawamata Y, Shino Y, Kasai T, Kubota K, Iwasaki H, et al. Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol. 2001;81:47–52.CrossRefPubMed
31.
go back to reference Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–91.CrossRefPubMed Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–91.CrossRefPubMed
32.
go back to reference de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76(Pt 4):1057–62.CrossRefPubMed de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76(Pt 4):1057–62.CrossRefPubMed
33.
go back to reference Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefèvre P, et al. Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol. 2007;45:928–34.CrossRefPubMedPubMedCentral Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefèvre P, et al. Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol. 2007;45:928–34.CrossRefPubMedPubMedCentral
34.
go back to reference Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791–5.PubMedPubMedCentral Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791–5.PubMedPubMedCentral
35.
go back to reference Altman D. Practical statistics for medical research. London: Chapman and Hall/CRC press; 1990. Altman D. Practical statistics for medical research. London: Chapman and Hall/CRC press; 1990.
36.
37.
go back to reference Mohammadi S, Esfahani BN, Moghim S, Mirhendi H, Zaniani FR, Safaei HG, et al. Optimal DNA isolation method for detection of Nontuberculous mycobacteria by polymerase chain reaction. Adv Biomed Res. 2017;6:133.CrossRefPubMedPubMedCentral Mohammadi S, Esfahani BN, Moghim S, Mirhendi H, Zaniani FR, Safaei HG, et al. Optimal DNA isolation method for detection of Nontuberculous mycobacteria by polymerase chain reaction. Adv Biomed Res. 2017;6:133.CrossRefPubMedPubMedCentral
38.
go back to reference Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol. 2004;30:302–8.CrossRefPubMed Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol. 2004;30:302–8.CrossRefPubMed
39.
go back to reference Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M, et al. Detection by PCR of human papillomavirus in Colombia: comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods. 2011;178:68–74.CrossRefPubMed Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M, et al. Detection by PCR of human papillomavirus in Colombia: comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods. 2011;178:68–74.CrossRefPubMed
40.
go back to reference Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005;43:1171–7.CrossRefPubMed Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005;43:1171–7.CrossRefPubMed
41.
42.
go back to reference Del Pino M, Alonso I, Rodriguez-Trujillo A, Bernal S, Geraets D, Guimerà N, et al. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection. J Virol Methods. 2017;248:238–43.CrossRefPubMed Del Pino M, Alonso I, Rodriguez-Trujillo A, Bernal S, Geraets D, Guimerà N, et al. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection. J Virol Methods. 2017;248:238–43.CrossRefPubMed
43.
go back to reference Aruhuri B, Tarivonda L, Tenet V, Sinha R, Snijders PJF, Clifford G, et al. Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res (Phila Pa). 2012;5:746–53.CrossRef Aruhuri B, Tarivonda L, Tenet V, Sinha R, Snijders PJF, Clifford G, et al. Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res (Phila Pa). 2012;5:746–53.CrossRef
44.
go back to reference Kulmala S-M, Syrjänen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol. 2004;42:2470–5.CrossRefPubMedPubMedCentral Kulmala S-M, Syrjänen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol. 2004;42:2470–5.CrossRefPubMedPubMedCentral
45.
go back to reference de Thurah L, Bonde J, Lam JUH, Rebolj M. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review. Clin Microbiol Infect. 2018;24:29–36.CrossRefPubMed de Thurah L, Bonde J, Lam JUH, Rebolj M. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review. Clin Microbiol Infect. 2018;24:29–36.CrossRefPubMed
46.
go back to reference Allende G, Surriabre P, Cáceres L, Bellot D, Ovando N, Torrico A, et al. Evaluation of the self-sampling for cervical cancer screening in Bolivia. BMC Public Health. 2019;19:80.CrossRefPubMedPubMedCentral Allende G, Surriabre P, Cáceres L, Bellot D, Ovando N, Torrico A, et al. Evaluation of the self-sampling for cervical cancer screening in Bolivia. BMC Public Health. 2019;19:80.CrossRefPubMedPubMedCentral
Metadata
Title
Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
Authors
Pedro Surriabre
Andrea Torrico
Tania Vargas
Fuantina Ugarte
Patricia Rodriguez
Véronique Fontaine
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4527-9

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.